Vanguard Portfolio Management
BBIO icon

Vanguard Portfolio Management’s BridgeBio Pharma BBIO Stock Holding History

Vanguard Portfolio Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$570M Sell
7,656,722
-423,851
-5% -$29.7M 0.03% 661
2026
Q1 		$600M Buy
+8,080,573
New +$586M 0.03% 586

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management's BBIO Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its BridgeBio Pharma (BBIO) stake by 5.2% in Q2 2026, selling an estimated $29.7M and leaving 7,656,722 shares worth $570M. The position accounts for 0.03% of the portfolio, ranked #661.

Vanguard Portfolio Management first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $600M in Q1 2026. 439 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Vanguard Portfolio Management held 7,656,722 shares of BridgeBio Pharma worth $570M as of Q2 2026.
  • Vanguard Portfolio Management sold 423,851 BridgeBio Pharma shares in Q2 2026, an estimated $29.7M.
  • BridgeBio Pharma made up 0.03% of Vanguard Portfolio Management's portfolio in Q2 2026, its #661 holding.
  • Vanguard Portfolio Management first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's BridgeBio Pharma position peaked at $600M in Q1 2026.
  • 439 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.